Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: A nationwide cohort study

KUO-HSING CHENYU-YUN SHAOChen H.-M.Lin Y.-L.ZHONG-ZHE LINLai M.-S.ANN-LII CHENGKUN-HUEI YEH2022-06-102022-06-1020161471-2407https://www.scopus.com/inward/record.uri?eid=2-s2.0-84970016836&doi=10.1186%2fs12885-016-2358-2&partnerID=40&md5=91d3bc0282e8a9a4eda6fb6f6b7d4382https://scholars.lib.ntu.edu.tw/handle/123456789/612563[SDGs]SDG3Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: A nationwide cohort studyjournal article10.1186/s12885-016-2358-2272217312-s2.0-84970016836